Short Interest Worth Mentioning Today: Is Buying Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB), Having Higher Short Interest a Winning Strategy?

November 28, 2016 - By Linda Rogers   ·   0 Comments

Short Interest Worth Mentioning Today: Is Buying Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB), Having Higher Short Interest a Winning Strategy?

The stock of Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) registered an increase of 67.28% in short interest. CATB’s total short interest was 379,400 shares in November as published by FINRA. Its up 67.28% from 226,800 shares, reported previously. With 79,500 shares average volume, it will take short sellers 5 days to cover their CATB’s short positions. The short interest to Catabasis Pharmaceuticals Incorporated’s float is 5.65%. About 28,668 shares traded hands. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined 22.38% since April 25, 2016 and is downtrending. It has underperformed by 28.39% the S&P500.

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $71.72 million. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted , a linker drug discovery platform. It currently has negative earnings. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Ratings Coverage

Out of 2 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Catabasis Pharmaceuticals has been the topic of 4 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Wedbush given on Monday, August 17. Wedbush maintained Catabasis Pharmaceuticals Inc (NASDAQ:CATB) rating on Wednesday, June 8. Wedbush has “Outperform” rating and $17 price target. The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has “Buy” rating given on Thursday, June 9 by Citigroup. Citigroup maintained the stock with “Buy” rating in Tuesday, March 22 report.

CATB Company Profile

Catabasis Pharmaceuticals, Inc., incorporated on June 26, 2008, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Firm is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. The Company’s CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

More notable recent Catabasis Pharmaceuticals Inc (NASDAQ:CATB) news were published by: Marketwatch.com which released: “Catabasis shares plummet 51% after drug trial misses goal” on April 24, 2015, also Quotes.Wsj.com with their article: “News Catabasis Pharmaceuticals Inc.CATB” published on February 02, 2015, Globenewswire.com published: “Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) to Ring The Nasdaq Stock Market …” on November 16, 2016. More interesting news about Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were released by: Businesswire.com and their article: “Catabasis Pharmaceuticals Initiates MoveDMD, a Phase 1/2 Trial of CAT-1004 for …” published on June 17, 2015 as well as Barrons.com‘s news article titled: “Catabasis Pharmaceuticals Shares Could Double” with publication date: July 20, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>